课题基金 / 基金详情

A Pluripotent Stem Cell Reagent for Corneal Regeneration

A Pluripotent Stem Cell Reagent for Corneal Regeneration
用于角膜再生的多能干细胞试剂
批准号:
8626779
负责人:
JAMES L FUNDERBURGH
金额:
$19.14万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-12-01 至 2015-11-30

项目摘要

项目成果

JAMES L FUNDERBURGH的其他基金

相似基金

相关文献

中文摘要
翻译
在美国,每年约有4万人因角膜混浊而需要进行角膜移植手术,最高可达1000万人 全世界的人都患有双眼角膜失明。大多数受影响的人不接受治疗 因为组织不能移植。获取捐赠者角膜的困难促使人们研究 角膜再生的替代方法,包括组织生物工程和直接细胞 心理治疗。同种异体组织耐受性好的事实促进了基于细胞的治疗的可能性 移植后很少发生排斥反应。设备和细胞治疗的最新进展 使用动物模型的方法显示了角膜病理的生物工程解决方案的巨大前景 间质和内皮。然而,细胞技术进步的一个主要障碍是一个来源 对细胞来说。在角膜基质和角膜内皮细胞以及成体干细胞的情况下 细胞,在培养中扩增的潜力是有限的,并且细胞的性质因个体而异。 捐赠者和制备方法,在一致性和质量控制方面是一个挑战。 在这个项目中,我们将开发一种基于干细胞的试剂,用于使用人类胚胎进行角膜工程 干细胞(HESC),利用hESC研究的两个最新进展。我们的实验室有 证实了hESC转化为角膜祖细胞。我们发现角膜祖细胞 容易分化为人类角质形成细胞。与此同时,其他研究人员描述了一种新的方法来 从hESC中产生基本上无限数量的同质神经脊细胞。我们建议联合 这些技术用于产生标准化的hESC来源的干细胞试剂,具有分化的潜力 直接进入角膜基质细胞和角膜内皮细胞。该项目将:(1)定义标准操作 从hESC生成角膜祖细胞的程序。(2)展示同质性、稳定性、安全性和 人胚胎干细胞来源的角膜前体细胞的冷冻保存。(3)研制两种基于hESC的荧光报告材料 用于评估角膜基质细胞和内皮细胞来源的质量和均质性的细胞系 来自hESC的。(4)利用体外功能实验验证hESC来源的角膜细胞的功能。 化验。该项目应用新的技术发展来解决角膜细胞的一个重要障碍- 以再生医学为基础。该项目的成功完成将提供一个定义明确、安全、基于细胞的 可无限量使用的试剂用于生物工程和细胞治疗方法 改善角膜失明。
英文摘要
About 40,000 individuals annually require keratoplasty for corneal opacity in the USA and up to 10 million people world-wide suffer bilateral corneal blindness. Most affected individuals do not receive treatment because tissue is not available to transplant. Difficulty in obtaining donor corneas has spurred research into alternative approaches to corneal regeneration including bioengineering of tissues and direct cell-based therapy. The potential for cellular based therapy is facilitated by the fact that allogenic tissues are well tolerated and seldom rejected after transplantation. Recent advances in devices and in cell-based therapeutic approaches using animal models show great promise for bioengineering solutions to pathologies of the corneal stroma and endothelium. A major barrier to the advancement of cell-based technologies, however, is a source for cells. In the case of keratocytes of corneal stroma and corneal endothelial cells, as well as of adult stem cells, the potential for expansion in culture is limited, and the properties of the cells vary according to individual donors and preparation methods, presenting a challenge in terms of consistency and quality control. In this project we will develop a stem cell-based reagent for corneal engineering using human embryonic stem cells (hESC), taking advantage of two recent developments in hESC research. Our lab has demonstrated conversion of hESC into corneal progenitor cells. We showed that the corneal progenitor cells readily differentiate to human keratocytes. Simultaneously, other researchers described a new method to produce essentially limitless numbers of homogeneous neural crest cells from hESC. We propose to combine these techniques to generate a standardized hESC-derived stem cell reagent with the potential to differentiate directly into corneal keratocytes and corneal endothelial cells. The project will: (1) Define a standard operating procedure to generate corneal progenitor cells from hESC. (2) Demonstrate homogeneity, stability, safety, and cryo-storage of the hESC-derived corneal progenitor cells. (3) Develop two hESC-based fluorescent reporter cell lines used to assess the quality and homogeneity of the corneal keratocytes and endothelial cells derived from the hESC. (4) Demonstrate functionality of the hESC-derived corneal cells using in vitro functional assays. This project applies novel technical developments to address an important barrier to corneal cell- based regenerative medicine. Successful completion of this project will provide a well-defined, safe, cell-based reagent available in unlimited quantities for use in bioengineering and cytotherapeutic approaches for the amelioration of corneal blindness.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Bioengineering Cornea with Autologous Stem Cells
A Pluripotent Stem Cell Reagent for Corneal Regeneration
Stem Cells for Corneal Engineering
Stem Cells for Corneal Engineering
海外基金